Please find below a copy of a letter I have just sent to PSNC. Please feel free to copy and paste it into an email and send them a copy.
-------------------------------------------------------------------------------------------------------------------Sent:: 25 April 2013 20:56
To:'info@psnc.org.uk'
Cc: 'RIS.NA@mhra.gsi.gov.uk'; 'duncan.selbie@dh.gsi.gov.uk'; 'huntj@parliament.uk'
Subject:The unacceptably high cost of Liothyronine
Dear PSNC
I have been reading on the Department of Health website how a new healthcare system is designed to empower patients and local communities, the website says the new system is designed to deliver better health, better care and better value for money. healthandcare.dh.gov.uk/gui...
I would like to test this notion of ‘empowering patients and listening to communities’ and in the spirit of that concept would like to bring to your attention an issue which I believe may save the NHS a significant amount of money.
I have been viewing your website and find that the cost to the NHS of a pack of 28 Liothyronine (T3) is £52.46 (psnc.org.uk/data/files/Brok... ). It is my belief, and the belief of many other Hypothyroid patients that Liothyronine may provide a more effective alternative therapy for Hypothyroidism, for patients who do not readily convert T4 into T3. thyroiduk.healthunlocked.com/ (for views of an on-line community of thyroid patients, please see tags on this website listed under the Tags A-Z for T3, Liothyronine, t4 to t3 conversion).
Many patients have asked their GPs and Endocrinologists to prescribe Liothyronine, however, many requests are met with barriers, one of which is ‘cost’.
I would like to bring to your attention an alternative product which is made by Adbi Ibrahim a pharmaceutical company in Turkey, with a London office. This company produced a product named Tiromel which is available in 25 mcg tablets (100 tablets per pack) at a cost of £3.50 per pack abdiibrahim.com.tr/en/produ...
If this product were available in the UK, doctors would not be worried about the cost, then vast numbers of hypothyroid patients would gain access to an alternative therapy which is likely to produce positive effects (T3 being the active hormone, whereas T4 is only the ‘raw material’ and in itself of little use, if not converted to T3).
As a taxpayer I am absolutely disgusted that so much public money is being wasted in this way and that as a result very many hypothyroid patients are being denied access to a therapy that is likely to considerably improve their quality of life.
I have already written to the MRHA to ask for this product to be licensed
I look forward to receiving a full explanation as to why this product cannot be made available on the NHS and the justification for continuing to line the pockets of Mercury Pharma shareholders at the expense of the British taxpayer.
Yours faithfully